- Status:
- Red
- Decision Date:
- September 2019
Comments
RED:
- NICE TA596 - treatment of moderate-to-severe plaque psoriasis
- NICE TA803 - Risankizumab for treating active psoriatic arthritis after
inadequate response to DMARDs. (Decision date - August 2022)
- NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease. (Decision date - June 2023)
ICB commissioned
search again